ArchiMed Acquires Majority Stake in NAMSA
September 1, 2020
ArchiMed, a healthcare-focused private equity firm, acquired a majority interest in NAMSA from the founding Gorski Family in an undisclosed equity recapitalization. NAMSA's president and senior management retained a significant double-digit stake; ArchiMed said the investment will support NAMSA's international growth and buy‑and‑build strategy to broaden services and accelerate expansion.
- Buyers
- ArchiMed
- Targets
- NAMSA
- Sellers
- Gorski Family
- Industry
- Healthcare Services
- Location
- Ohio, United States
- Transaction Type
- Recapitalization
Explore More
Related Acquisitions
-
NAMSA Acquires SUAZIO
March 27, 2023
Healthcare Services
ARCHIMED-funded NAMSA has acquired SUAZIO, a Belgium-headquartered, data-driven life sciences and MedTech marketing and research consultancy. The add-on expands NAMSA's strategic consulting, market research and commercialization capabilities across medical devices and IVD markets; SUAZIO's founder reinvested proceeds and will continue to lead its consultancy services.
-
NAMSA to Acquire Belgium-Based Medanex Clinic
March 30, 2022
Healthcare Services
NAMSA, a global MedTech contract research organization (CRO), announced it is nearing the acquisition of Medanex Clinic, a Belgium-based European preclinical research organization. The deal is intended to expand NAMSA’s early-stage preclinical and specifically cardiovascular preclinical capabilities in Europe.
-
ARCHIMED (MED Platform I) Acquires Majority Stake in CARSO
December 16, 2021
Healthcare Services
Transatlantic healthcare private equity firm ARCHIMED, via its MED Platform I fund and in partnership with CAPZA Expansion and Siparex, has acquired a majority stake in Lyon-based CARSO, a leader in purity and analytical testing for pharma, healthcare, environmental and food sectors. The deal (debt provided by Tikehau Capital and several banks) will support CARSO's internationalization and service-range expansion as the group aims to more than double current annual revenues (above €200 million).
-
NAMSA (ARCHIMED) Acquires Clinlogix
August 2, 2021
Healthcare Services
Toledo-based NAMSA, a portfolio company of healthcare-focused private equity firm ARCHIMED, has acquired Clinlogix, a Lower Gwynedd, Pennsylvania-based contract research organization (CRO) focused on medical device clinical trials. The deal expands NAMSA's clinical trial capacity by roughly 25%, deepens therapeutic expertise in neurology, oncology, urology and nephrology, and strengthens global trial capabilities with Clinlogix facilities in Japan, Germany and Colombia.
-
NAMSA Acquires American Preclinical Services (APS)
March 2, 2021
Medical Devices
Toledo-based NAMSA, a medical-device-focused contract research organization owned by ARCHIMED's MED Platform I, has acquired Minneapolis-based American Preclinical Services (APS). The add-on expands NAMSA's lab, surgical instrumentation and imaging capabilities and increases its footprint in Minnesota; debt financing for the deal was provided by funds managed by Ares Management Corporation.
-
NAMSA Acquires Syntactx
January 5, 2021
Healthcare Services
NAMSA, a medical device–focused contract research organization (and portfolio company of ArchiMed), has acquired New York–based CRO Syntactx. The add-on purchase expands NAMSA’s clinical research, electronic data capture (EDC), core lab imaging, safety and cardiovascular regulatory consulting capabilities to better serve global medtech sponsors.
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.